Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy

Clinical Endocrinology

Volumn 85, Issue 1, 2016, Pages 137-149

  Chan, Jean L ^a   Koda, Joy ^a   Heilig, Joseph S ^b   Cochran, Elaine K ^c   Gorden, Phillip ^c   Oral, Elif A ^d   Brown, Rebecca J ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; LEPTIN; METRELEPTIN; METRELEPTIN ANTIBODY; PRAMLINTIDE; UNCLASSIFIED DRUG; AMYLIN;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; COMORBIDITY; FOLLOW UP; HUMAN; IMMUNOGENICITY; LIPODYSTROPHY; METABOLIC REGULATION; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; WEIGHT GAIN; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CHILD; CONTROLLED STUDY; FEMALE; IMMUNOGENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODY FORMATION; CHILD; FEMALE; HUMANS; IMMUNOGENETIC PHENOMENA; ISLET AMYLOID POLYPEPTIDE; LEPTIN; LIPODYSTROPHY; MALE; MIDDLE AGED; OBESITY; YOUNG ADULT;

EID: 84973863192     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12980     Document Type: Article

References (25)

1. Zhang, Y., Proenca, R., Maffei, M., et al,. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature, 372, 425-432.
2. Friedman, J., (2014) 20 years of leptin: leptin at 20: an overview. Journal of Endocrinology, 223, T1-T8.
3. Heymsfield, S.B., Greenberg, A.S., Fujioka, K., et al,. (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA, 282, 1568-1575.
4. Ravussin, E., Smith, S.R., Mitchell, J.A., et al,. (2009) Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring), 17, 1736-1743.
5. Roth, J.D., Roland, B.L., Cole, R.L., et al,. (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proceedings of the National Academy of Sciences of the United States of America, 105, 7257-7262.
6. Chan, J.L., &, Oral, E.A., (2010) Clinical classification and treatment of congenital and acquired lipodystrophy. Endocrine Practice, 16, 310-323.
7. Garg, A., (2004) Acquired and inherited lipodystrophies. New England Journal of Medicine, 350, 1220-1234.
8. Garg, A., (2011) Clinical review#: lipodystrophies: genetic and acquired body fat disorders. Journal of Clinical Endocrinology and Metabolism, 96, 3313-3325.
9. Chan, J.L., Lutz, K., Cochran, E., et al,. (2011) Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocrine Practice, 17, 922-932.
10. Chong, A.Y., Lupsa, B.C., Cochran, E.K., et al,. (2010) Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia, 53, 27-35.
11. Javor, E.D., Cochran, E.K., Musso, C., et al,. (2005) Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes, 54, 1994-2002.
12. Oral, E.A., Simha, V., Ruiz, E., et al,. (2002) Leptin-replacement therapy for lipodystrophy. New England Journal of Medicine, 346, 570-578.
13. AstraZeneca (2014) MYALEPT (metreleptin) prescribing information.
14. Baker, M.P., Reynolds, H.M., Lumicisi, B., et al,. (2010) Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself, 1, 314-322.
15. Schnabel, C.A., Fineberg, S.E., &, Kim, D.D., (2006) Immunogenicity of xenopeptide hormone therapies. Peptides, 27, 1902-1910.
16. Weeraratne, D.K., Kuck, A.J., Chirmule, N., et al,. (2013) Measurement of anti-erythropoiesis-stimulating agent IgG4 antibody as an indicator of antibody-mediated pure red cell aplasia. Clinical and Vaccine Immunology, 20, 46-51.
17. Wang, Y., &, Heilig, J.S., (2012) Differentiation and quantification of endogenous and recombinant-methionyl human leptin in clinical plasma samples by immunocapture/mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 70, 440-446.
18. Crouse, J.A., Elliott, G.E., Burgess, T.L., et al,. (1998) Altered cell surface expression and signaling of leptin receptors containing the fatty mutation. Journal of Biological Chemistry, 273, 18365-18373.
19. Procaccini, C., Jirillo, E., &, Matarese, G., (2012) Leptin as an immunomodulator. Molecular Aspects of Medicine, 33, 35-45.
20. Farooqi, I.S., Matarese, G., Lord, G.M., et al,. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. Journal of Clinical Investigation, 110, 1093-1103.
21. Licinio, J., Caglayan, S., Ozata, M., et al,. (2004) Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proceedings of the National Academy of Sciences of the United States of America, 101, 4531-4536.
22. Considine, R.V., Sinha, M.K., Heiman, M.L., et al,. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine, 334, 292-295.
23. Haque, W.A., Shimomura, I., Matsuzawa, Y., et al,. (2002) Serum adiponectin and leptin levels in patients with lipodystrophies. Journal of Clinical Endocrinology and Metabolism, 87, 2395.
24. Beltrand, J., Beregszaszi, M., Chevenne, D., et al,. (2007) Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics, 120, e291-e296.
25. Beltrand, J., Lahlou, N., Le Charpentier, T., et al,. (2010) Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. European Journal of Endocrinology, 162, 1083-1091.